Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity follow-up of altSonflex1-2-3 Shigella vaccine in African children
2026-000201-13Phase 2
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of altSonflex1-2-3 in shigellosis, sponsored by GSK. Primary endpoint: Anti-serotype specific Shigella LPS/O-antigen serum IgG.
02
Drugs
altSonflex1-2-3
03
Conditions
shigellosis
Beyond the preview
Go deeper on 2026-000201-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000201-13.